# KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

> **NCT07260812** · PHASE1 · RECRUITING · sponsor: **TCRx Therapeutics Co.Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** KSV01 Injection

## Key facts

- **NCT ID:** NCT07260812
- **Lead sponsor:** TCRx Therapeutics Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260812, "KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07260812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*